IVA News and Press, Inventiva S.A. From 03/08/22

Inventiva S.A. (IVA) Q4 2021 Earnings Conference Call March 08, 2022 08:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier -...

Inventiva (NASDAQ:IVA) said the U.S. Food and Drug Administration (FDA) concluded that a phase 2 trial of the company's drug lanifibranor in combination empagliflozin to treat patients with non-cirrhotic NASH and Type 2 Diabetes (T2D) may proceed. The decision was made by the FDA after t...

Inventiva press release (NASDAQ:IVA): Q4 GAAP EPS of -€1.27. Revenue of €4.2M (+950.0% Y/Y). For further details see: Inventiva GAAP EPS of -€1.27, revenue of €4.2M

Inventiva (NASDAQ:IVA): 9M Revenue of €0.2M Cash and cash equivalents of €105.7M. Press Release For further details see: Inventiva reports Q3 results

Inventiva S.A. (IVA) Q2 2021 Results Conference Call September 21, 2021 08:00 AM ET Company Participants Frédéric Cren - Chairman, CEO and Co-Founder Pierre Broqua - CSO and Co-Founder Michael Cooreman - CMO Jean Volatier - CFO Conference Call Participants Lucy Codrington - Jefferie...

The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVA) Investor Presentation - Slideshow

Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...

Inventiva S.A. (IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 08:00 ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief...

The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow

Clinical-stage biopharmaceutical company Inventiva (IVA) announces the details of the Phase 3 trial evaluating its lead drug candidate lanifibranor in NASH following the end-of-Phase 2 meeting with the FDA.Non-alcoholic steatohepatitis ((NASH)), is a fatty liver disease due to obesity.As...